LAS VEGAS, June 9, 2014 /PRNewswire/ -- CannaVest
Laboratories, a division of CannaVest Corp. (OTC:BB CANV), the
producer of the award winning cannabidiol CBD Plus Oil™, and the
wholly owned subsidiary and laboratory division of CannaVest
Corporation, the world's largest industrial hemp and cannabidiol
(CBD) oil distribution company- is pleased to announce the
appointment of renowned cannabinoid Scientist Dr. Alexandros Makriyannis, to lead its Scientific
Advisory Board. Dr. Makriyannis is the current George D. Behrakis
Endowed Chair in Pharmaceutical Biotechnology, a Professor of
Chemistry, Chemical Biology and Pharmaceutical Sciences, and the
Director of the Center for Drug Discovery at Northeastern University. Dr. Makriyannis holds over
40 US Patents, has been a consultant for several major US
pharmaceutical companies, and has co-authored over 400
peer-reviewed scientific publications. Through his
multidisciplinary work encompassing both chemistry and biology, Dr.
Makriyannis has been a pioneer in chemical biology even before this
designation was coined. He was among the first to define the
biochemical pathways of endocannabinoids within the human
endocannabinoid system (ECS). CannaVest Laboratories' lead research
scientist Dr. Joshua Hartsel states
that, "This historic partnership with Dr. Makriyannis, will enable
CannaVest Laboratories to strategically and rapidly expand our
capabilities."
Endocannabinoids are naturally occurring compounds
(neurotransmitters) that together with receptors (such as CB1 and
CB2) regulate and modulate the ECS, which controls crucial
physiological processes in the body such
as appetite, pain-sensation, mood, and memory.
Endocannabinoids share some of the biological properties of
plant-based cannabinoids, like cannabidiol or CBD, a valuable
non-psychoactive nutraceutical product isolated from industrial
hemp, and the main ingredient in CBD Plus Oil™. Dr. Makriyannis'
laboratory, at his Boston
based drug discovery start-up, MAKScientific, has been involved in
many advances in cannabinoid chemistry and biology and has produced
some breakthrough compounds that are being used by many research
laboratories worldwide. Some of these are in the late
pre-clinical stage of drug development.
Dr. Joshua Hartsel, CannaVest
Laboratories' lead research scientist says, "I have always admired
Dr. Makriyannis' outstanding contributions to the field, and
have been following his publications since graduate school.
Dr. Makriyannis is an excellent scientific resource, who has
clearly demonstrated his ability to develop effective consumer-end
products. This relationship will facilitate new methods that will
improve our current product's purity and CannaVest Laboratories'
processing speed and efficacy. Throughout his career
Dr. Makriyannis has developed extensive relationships with
specialists within the industry. These relationships will allow
CannaVest to bring the appropriate scientists together to assist in
strategic decision-making processes. In addition, we will
collaborate directly with Dr. Makriyannis' Boston lab and MAKScientific."
Given it's amazing potential, the ECS has become an attractive
target for pharmaceutical drug development. CBD is the most studied
non-THC cannabinoid, which possesses great therapeutic potential to
relieve ailments from convulsions, inflammation, anxiety and
nausea. CannaVest Laboratories' was designed to facilitate cutting
edge research on CBD. Dr. Hartsel and the CannaVest Laboratory
team have made some significant scientific contributions to the
burgeoning industrial hemp nutraceutical movement by concentrating
supercritical CO2 extracted hemp oil, into high value CBD-rich
products. CBD Plus Oil™ has earned recognition for the highest
cannabidiol (CBD) concentrates. Dr. Makriyannis' partnership will
expand the ways CBD can be used to optimize health– and lead to new
end-consumer products.
Dr. Makriyannis partnership with CannaVest Laboratories will
continue CannaVest's mission to educate the public on the health
benefits of CBD, to optimize purity and formulations, and to find
new product delivery systems.
About CannaVest Corp.
CannaVest Corp. is in the business of investing and
developing hemp-based cannabinoid Companies. CannaVest
Corp. also develops, produces, markets and sells end-consumer
products to the nutraceutical industry containing the hemp plant
extract, cannabidiol (CBD). Additionally, the company resells--to
third parties--raw product acquired by CannaVest
Corp. pursuant to the company's supply relationships
in Europe. CannaVest Corp. seeks to take advantage
of an emerging worldwide trend to re-energize the production of
industrial hemp and to foster its many uses for consumers.
Cannabinoids (cannabidiol/CBD) are natural constituents of the hemp
plant, and CBD is derived from hemp stalk and seed. Additional
information is available from OTCMarkets.com or by visiting
CannaVest.com.
About US Hemp Oil
US Hemp Oil seeks to develop the United
States industrial hemp industry. The company is dedicated to
the procurement, processing, marketing and distribution of bulk
wholesale hemp seed, hemp oil, protein, food and hemp body care
products. US Hemp Oil is determined to bring hemp products into the
mainstream by creating greater public awareness of and media
exposure for the exceptional nutritional profile of hemp and the
environmental benefits of growing industrial hemp. For more
information, please visit: USHempOil.com
About CannaVest Laboratories
The CannaVest laboratories was designed to facilitate cutting
edge research on cannabidiol (CBD). CBD is a valuable
non-psychoactive nutraceutical product isolated from industrial
hemp. The labs, located in the heart of San Diego, CA, has recently made some
significant scientific contributions to the burgeoning industrial
hemp movement currently taking place in the United States and around the world. Dr.
Joshua Hartsel (lead research
scientist) and Greg Waterbury
(Project Manager) are equipped with state of the art
high-performance liquid chromatography (HPLC), gas chromatography
(GC), mass spectrometry (MS), process chromatography, and
distillation tools to produce award winning pharmaceutical-grade
CBD. In addition to a full portfolio of scientific instrumentation,
Dr. Hartsel previously served as a board member on the Association
of California Cannabis Laboratories and was the founder of Delta-9
Technologies, an analytical testing company dedicated to the
quality control of cannabis products. The CannaVest laboratory has
adopted the industry standard techniques to evaluate hemp for
cannabinoid content, terpene profiles, pesticide residues, and
microbial contamination.
FORWARD-LOOKING DISCLAIMER
This press release may
contain certain forward-looking statements and information, as
defined within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, and is
subject to the Safe Harbor created by those sections. This
material contains statements about expected future events and/or
financial results that are forward-looking in nature and subject to
risks and uncertainties. Such forward-looking statements by
definition involve risks, uncertainties and other factors, which
may cause the actual results, performance or achievements of
CannaVest Corp. to be materially different from the statements made
herein.
LEGAL DISCLOSURE
CannaVest Corp. does not sell or
distribute any products that are in violation of the United States
Controlled Substances Act (US.CSA). The company does grow, sell and
distribute hemp-based products and are involved with the federally
legal distribution of medical marijuana-based products within
certain international markets.
Corporate Contact:
CannaVest Corp.
2688 S. Rainbow Blvd., Ste. B
Las Vegas, NV 89146
Office: 866-290-2157
Logo
- http://photos.prnewswire.com/prnh/20140403/LA98016LOGO
SOURCE CannaVest Corp.